Oesophageal lichen planus: the efficacy of topical steroid-based therapies

A. Podboy, D. Sunjaya, Thomas Christopher Smyrk, Joseph A Murray, M. Binder, David A Katzka, J. A. Alexander, Magnus Halland

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background: Oesophageal lichen planus is an idiopathic inflammatory disorder characterized by significant oesophageal stricturing. Oesophageal lichen planus is a rare, difficult to diagnose, and likely an under recognized disease. As a result, there is no standardized approach to therapy and treatment strategies vary. Aim: To examine the utility of topical steroid therapy (fluticasone or budesonide) in the management of oesophageal lichen planus. Methods: A retrospective chart review was conducted of patients diagnosed with oesophageal lichen planus who underwent baseline and follow up endoscopy pre and post topical steroid therapy between 1995 and 2016 at Mayo Clinic, Rochester MN. Average time between upper GI endoscopy was 3.2 months (0.7–11.7). Swallowed steroid preparations included fluticasone 880 μg twice daily or budesonide 3 mg twice daily. Patients were reviewed for symptomatic response to therapy using the Dakkak-Bennett dysphagia score (0–4, no dysphagia to total aphagia). Pre- and post-endoscopic findings were assessed. Additional baseline demographic, endoscopic, and histologic data were also obtained. Results: We identified 40 patients who met the inclusion criteria. A significant reduction in median dysphagia score from 1 (0–4) to 0 (0–3) after steroid therapy (P < 0.001) was noted. 62% of patients reported resolution of their dysphagia after receiving topical corticosteroids. 72.5% had an endoscopic response to steroid therapy. Conclusion: Topical swallowed budesonide or fluticasone appear to effective treatment for oesophageal lichen planus.

Original languageEnglish (US)
Pages (from-to)310-318
Number of pages9
JournalAlimentary Pharmacology and Therapeutics
Volume45
Issue number2
DOIs
StatePublished - Jan 1 2017

Fingerprint

Lichen Planus
Steroids
Deglutition Disorders
Budesonide
Therapeutics
Endoscopy
Adrenal Cortex Hormones
Demography

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Oesophageal lichen planus : the efficacy of topical steroid-based therapies. / Podboy, A.; Sunjaya, D.; Smyrk, Thomas Christopher; Murray, Joseph A; Binder, M.; Katzka, David A; Alexander, J. A.; Halland, Magnus.

In: Alimentary Pharmacology and Therapeutics, Vol. 45, No. 2, 01.01.2017, p. 310-318.

Research output: Contribution to journalArticle

Podboy, A. ; Sunjaya, D. ; Smyrk, Thomas Christopher ; Murray, Joseph A ; Binder, M. ; Katzka, David A ; Alexander, J. A. ; Halland, Magnus. / Oesophageal lichen planus : the efficacy of topical steroid-based therapies. In: Alimentary Pharmacology and Therapeutics. 2017 ; Vol. 45, No. 2. pp. 310-318.
@article{6f8fd7a1e7904259afbd47bca5ff4cd4,
title = "Oesophageal lichen planus: the efficacy of topical steroid-based therapies",
abstract = "Background: Oesophageal lichen planus is an idiopathic inflammatory disorder characterized by significant oesophageal stricturing. Oesophageal lichen planus is a rare, difficult to diagnose, and likely an under recognized disease. As a result, there is no standardized approach to therapy and treatment strategies vary. Aim: To examine the utility of topical steroid therapy (fluticasone or budesonide) in the management of oesophageal lichen planus. Methods: A retrospective chart review was conducted of patients diagnosed with oesophageal lichen planus who underwent baseline and follow up endoscopy pre and post topical steroid therapy between 1995 and 2016 at Mayo Clinic, Rochester MN. Average time between upper GI endoscopy was 3.2 months (0.7–11.7). Swallowed steroid preparations included fluticasone 880 μg twice daily or budesonide 3 mg twice daily. Patients were reviewed for symptomatic response to therapy using the Dakkak-Bennett dysphagia score (0–4, no dysphagia to total aphagia). Pre- and post-endoscopic findings were assessed. Additional baseline demographic, endoscopic, and histologic data were also obtained. Results: We identified 40 patients who met the inclusion criteria. A significant reduction in median dysphagia score from 1 (0–4) to 0 (0–3) after steroid therapy (P < 0.001) was noted. 62{\%} of patients reported resolution of their dysphagia after receiving topical corticosteroids. 72.5{\%} had an endoscopic response to steroid therapy. Conclusion: Topical swallowed budesonide or fluticasone appear to effective treatment for oesophageal lichen planus.",
author = "A. Podboy and D. Sunjaya and Smyrk, {Thomas Christopher} and Murray, {Joseph A} and M. Binder and Katzka, {David A} and Alexander, {J. A.} and Magnus Halland",
year = "2017",
month = "1",
day = "1",
doi = "10.1111/apt.13856",
language = "English (US)",
volume = "45",
pages = "310--318",
journal = "Alimentary Pharmacology and Therapeutics",
issn = "0269-2813",
publisher = "Wiley-Blackwell",
number = "2",

}

TY - JOUR

T1 - Oesophageal lichen planus

T2 - the efficacy of topical steroid-based therapies

AU - Podboy, A.

AU - Sunjaya, D.

AU - Smyrk, Thomas Christopher

AU - Murray, Joseph A

AU - Binder, M.

AU - Katzka, David A

AU - Alexander, J. A.

AU - Halland, Magnus

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: Oesophageal lichen planus is an idiopathic inflammatory disorder characterized by significant oesophageal stricturing. Oesophageal lichen planus is a rare, difficult to diagnose, and likely an under recognized disease. As a result, there is no standardized approach to therapy and treatment strategies vary. Aim: To examine the utility of topical steroid therapy (fluticasone or budesonide) in the management of oesophageal lichen planus. Methods: A retrospective chart review was conducted of patients diagnosed with oesophageal lichen planus who underwent baseline and follow up endoscopy pre and post topical steroid therapy between 1995 and 2016 at Mayo Clinic, Rochester MN. Average time between upper GI endoscopy was 3.2 months (0.7–11.7). Swallowed steroid preparations included fluticasone 880 μg twice daily or budesonide 3 mg twice daily. Patients were reviewed for symptomatic response to therapy using the Dakkak-Bennett dysphagia score (0–4, no dysphagia to total aphagia). Pre- and post-endoscopic findings were assessed. Additional baseline demographic, endoscopic, and histologic data were also obtained. Results: We identified 40 patients who met the inclusion criteria. A significant reduction in median dysphagia score from 1 (0–4) to 0 (0–3) after steroid therapy (P < 0.001) was noted. 62% of patients reported resolution of their dysphagia after receiving topical corticosteroids. 72.5% had an endoscopic response to steroid therapy. Conclusion: Topical swallowed budesonide or fluticasone appear to effective treatment for oesophageal lichen planus.

AB - Background: Oesophageal lichen planus is an idiopathic inflammatory disorder characterized by significant oesophageal stricturing. Oesophageal lichen planus is a rare, difficult to diagnose, and likely an under recognized disease. As a result, there is no standardized approach to therapy and treatment strategies vary. Aim: To examine the utility of topical steroid therapy (fluticasone or budesonide) in the management of oesophageal lichen planus. Methods: A retrospective chart review was conducted of patients diagnosed with oesophageal lichen planus who underwent baseline and follow up endoscopy pre and post topical steroid therapy between 1995 and 2016 at Mayo Clinic, Rochester MN. Average time between upper GI endoscopy was 3.2 months (0.7–11.7). Swallowed steroid preparations included fluticasone 880 μg twice daily or budesonide 3 mg twice daily. Patients were reviewed for symptomatic response to therapy using the Dakkak-Bennett dysphagia score (0–4, no dysphagia to total aphagia). Pre- and post-endoscopic findings were assessed. Additional baseline demographic, endoscopic, and histologic data were also obtained. Results: We identified 40 patients who met the inclusion criteria. A significant reduction in median dysphagia score from 1 (0–4) to 0 (0–3) after steroid therapy (P < 0.001) was noted. 62% of patients reported resolution of their dysphagia after receiving topical corticosteroids. 72.5% had an endoscopic response to steroid therapy. Conclusion: Topical swallowed budesonide or fluticasone appear to effective treatment for oesophageal lichen planus.

UR - http://www.scopus.com/inward/record.url?scp=85002342622&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85002342622&partnerID=8YFLogxK

U2 - 10.1111/apt.13856

DO - 10.1111/apt.13856

M3 - Article

C2 - 27859412

AN - SCOPUS:85002342622

VL - 45

SP - 310

EP - 318

JO - Alimentary Pharmacology and Therapeutics

JF - Alimentary Pharmacology and Therapeutics

SN - 0269-2813

IS - 2

ER -